Translation

PATENT COOPERATION TREATY

PCT/EP2003/014820

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 27483P WO	FOR FURTHER ACTION See Notification of Transmittal of Internation Preliminary Examination Report (Form PCT/IPEA/416			
International application No. PCT/EP2003/014820	International filing date (day/month/year) Priority date (day/month/year)			
International Patent Classification (IPC) or r G01N 33/53	ational classification and IPC			
Applicant	FEBIT BIOTECH GMBH			
2. This REPORT consists of a total of	5 sheets, including this cover sheet.			
This report is also accompanion amended and are the basis for 70.16 and Section 607 of the A	ed by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been this report and/or sheets containing rectifications made before this Authority (see Rule Administrative Instructions under the PCT).			
These annexes consist of a total	ofsheets.			
3. This report contains indications relati	ng to the following items:			
I Basis of the report				
II Priority				
III Non-establishment of	opinion with regard to novelty, inventive step and industrial applicability			
IV Lack of unity of invention				
	nder Article 35(2) with regard to novelty, inventive step or industrial applicability; ons supporting such statement			
VI Certain documents cite	od .			
VII Certain defects in the i	nternational application			
VIII Certain observations o	n the international application			
te of submission of the demand	Date of completion of this report			
01 March 2004 (01.03.20				
me and mailing address of the IPEA/EP	Authorized officer			
esimile No.	Telephone No.			

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

I. Basis of the report 1. With regard to the elements of the international application:* the international application as originally filed the description: pages pages pages the claims: pages 1-17 pages	
the international application as originally filed the description: pages pages pages the claims: pages 1-17	
the description: pages pages pages pages , filed with the letter of the claims: pages 1-17	
pages 1-15 pages	
pages	
pages pages , filed with the letter of the claims: pages 1-17	
the claims: pages 1-17	
the claims: pages 1-17	, filed with the demar
1-17	
pages 1-1/	
	, as originally file
pages, as amended (togeth	her with any statement under Article 1
pages	, filed with the deman
pages, filed with the letter of the drawings:	
Dages	
1/9-9/9	, as originally file
	<u> </u>
, filed with the letter of	
inc sequence using part of the description:	
pagespages	
pages, filed with the letter of, filed with the letter of, filed with the letter of With regard to the language, all the elements marked above were available or furnished to the international application was filed, unless otherwise indicated under this item.	
the language of a translation furnished for the purposes of international search (under R the language of publication of the international application (under Rule 48.3(b)). the language of the translation furnished for the purposes of international preliminary or 55.3).	
or 55.3).	y examination (under Rule 55.2 and/
With regard to any nucleotide and/or amino acid sequence disclosed in the interna preliminary examination was carried out on the basis of the sequence listing:	tional application, the international
contained in the international application in written form	
filed together with the international application in computer readable forms	
runnished subsequently to this Authority in written form.	
furnished subsequently to this Authority in computer readable form.	
international application as filed has been furnished	go beyond the disclosure in the
The statement that the information recorded in computer readable form is identical been furnished.	to the written sequence listing has
The amendments have resulted in the cancellation of:	
the description, pages	
the claims, Nos.	
the drawings, sheets/fig	
This report has been established as if (some of) the amendments had not been made, sin beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**	ice they have been considered to an
Replacement sheets which have been a second as the second	
Any replacement sheet containing such amendments must be referred to under item 1 and annexe	ed to this report.
m PCT/IPEA/409 (Box I) (July 1998)	j

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/EP 03/14820

YES

NO

V.	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement					
1.	Statement					
	Novelty (N)	Claims	1-17	YES		
		Claims		NO		
	Inventive step (IS)	Claims	1-17	YES		
		Claims		NO		
	Industrial applicability (IA)	Claims	1-17			

2. Citations and explanations

Reference is made to the following documents:

Claims

- WO 00/13018 A (FEBIT FERRARIUS BIOTECHNOLOGY; D1: LINDNER HANS (DE); MUELLER MANFRED (DE)) 9 March 2000 (2000-03-09)
- WO 02/089971 A (BEIER MARKUS; FEBIT AG (DE); MAURITZ D2: RALF (DE); STAEHLER CORD F (DE)) 14 November 2002 (2002-11-14)
- US-A-5 616 467 (OLSEN EGIL ET AL) 1 April 1997 D3: (1997-04-01)
- WO 02/32567 A (GUEIMIL RAMON; FEBIT AG (DE); D4: HEIDBREDE ANKE (DE); STAEHLER CORD F (D)) 25 April 2002 (2002-04-25).

Document D1 describes a method for the production of a support for determining analytes, wherein a microfluidic support with channels is used and a plurality of different receptor components (hybridization probes) is immobilized in a place- and/or time-specific manner, particularly by exposure to light.

According to the method for determining analytes, the support is brought into contact with a sample containing analytes and the analytes are determined by nucleic acid

hybridization, a plurality of hybridization probes, which each specifically bind with different analytes present in the sample, being arranged in different areas of the support.

Like document D1, document D2 also concerns a method for the production of a microfluidic support for the determination of analytes. The synthesis of the receptor components comprises the use of a combination of photochemical and wet chemical steps.

None of the available documents contains the deposition of hapten groups on the support used for the production of receptors. According to the present application, receptor synthesis is followed by staining of the support surface by the specific binding partner of the hapten group. In areas in which a receptor synthesis has been successful, staining by the binding partner is not possible (negative signal). This negative signal increases in intensity with the length of the receptor. The length of the receptor, that is to say, the success of the synthesis, can be detected by an increasing negative signal.

In the application, a universal detection of any number of different sequences is possible by a hapten detection reagent instead of through the control hybridization known from the prior art (see documents D1 to D4), which assumes knowledge of the composed receptor sequences. The method according to claims 1-2, 4-13 and 15-17 is suitable for controlling the quality of a receptor synthesis since the detection of the probe length and hence also the efficiency of the synthesis occurring at that position can be carried out universally, independently of a sequence, using a hapten detection reagent.

International application No. PCT/EP 03/14820

According to claims 3 and 14 the hapten groups are introduced into the receptors synthesized on the support in one or more positions. This method makes it possible to control the efficiency of the receptor synthesis on the basis of the number of hapten groups introduced into an area. Following receptor synthesis and contact with a hapten detection reagent, positive signals are produced. The intensity distribution of the signal correlates with the length of the receptor molecules. Even without hybridization the success of receptor synthesis can be verified directly after synthesis.

Consequently, claims 1-17 meet the requirements of PCT Article 33(2) and (3).

The applicant's attention is drawn to the fact that the spacers B and C specified in figure 6 (pages 8 and 9) do not correspond to the spacers described on page 13 and that this should be corrected (PCT Article 6).